Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | CCR6 | P51684 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 4/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.41 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 5/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | COMT | P21964 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17114060 | 0.86 | ESR1 (0.47) | HSP90AA1ESR1ESR2NPSR1NPC1 | |
| SCHEMBL7334559 | 0.79 | GRM5 (0.58) | ESR1ESR2GRM5NPC1RAB9A | |
| SCHEMBL12034643 | 0.71 | ESR1 (0.46) | ALDH1A1ESR1ESR2GRM5NPC1 | |
| SCHEMBL10835050 | 0.70 | ELANE (0.60) | LMNAALDH1A1NPSR1NPC1RAB9A | |
| SCHEMBL11609933 | 0.66 | LMNA (0.57) | LMNAALDH1A1HSP90AA1CCR6GRM5 | |
| SCHEMBL8884854 | 0.64 | CCR6 (0.35) | LMNAALDH1A1HSP90AA1CCR6ESR1 | |
| SCHEMBL11574035 | 0.64 | ALDH1A1 (1.00) | LMNAALDH1A1ESR1ESR2HCAR1 | |
| SCHEMBL28714 | 0.64 | — | — | |
| Orcinol SCHEMBL68497 | 0.64 | — | — | |
| SCHEMBL1013954 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215709-A1 | TYPE III DEIODINASE INHIBITORS AND USES THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215709-A1 | TYPE III DEIODINASE INHIBITORS AND USES THEREOF | TPO, DPP3, HSD17B3 | LMNA 4356/4885ALDH1A1 212/4885HSP90AA1 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.